000152993 001__ 152993 000152993 005__ 20251017144555.0 000152993 0247_ $$2doi$$a10.1111/ctr.13767 000152993 0248_ $$2sideral$$a116540 000152993 037__ $$aART-2020-116540 000152993 041__ $$aeng 000152993 100__ $$aSánchez Fructuoso, A. 000152993 245__ $$aEffectiveness and safety of the conversion to MeltDose® extended-release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: A retrospective study 000152993 260__ $$c2020 000152993 5203_ $$aTacrolimus is the cornerstone of immunosuppressive therapy after kidney transplantation. Its narrow therapeutic window mandates serum level strict monitoring and dose adjustments to ensure the optimal risk-benefit balance. This observational retrospective study analyzed the effectiveness and safety of conversion from twice-daily immediate-release tacrolimus (IR-Tac) or once-daily prolonged-release tacrolimus (PR-Tac) to the recent formulation once-daily MeltDose® extended-release tacrolimus (LCP-Tac) in 365 stable kidney transplant recipients. We compared kidney function three months before and three months after the conversion. Three months after conversion, the total daily dose was reduced ~35% (P <.0001), and improved bioavailability and stable serum LCP-Tac concentrations were observed. There was no increase in the number of patients requiring tacrolimus dose adjustments after conversion. Renal function was unaltered, and no cases of BPAR were reported. Reports of tremors, as collected in the clinical histories for each patient, decreased from pre-conversion (20.8%) to post-conversion (11.8%, P <.0001). LCP-Tac generated a cost reduction of 63% compared with PR-Tac. In conclusion, the conversion strategy to LCP-Tac from other tacrolimus formulations in stable kidney transplant patients showed safety and effectiveness in a real-world setting, confirming the data from RCTs. The specific pharmacokinetic properties of LCP-Tac could be potentially advantageous in patients with tacrolimus-related adverse events. 000152993 540__ $$9info:eu-repo/semantics/closedAccess$$aby-nc$$uhttps://creativecommons.org/licenses/by-nc/4.0/deed.es 000152993 590__ $$a2.863$$b2020 000152993 591__ $$aSURGERY$$b80 / 210 = 0.381$$c2020$$dQ2$$eT2 000152993 591__ $$aTRANSPLANTATION$$b15 / 25 = 0.6$$c2020$$dQ3$$eT2 000152993 592__ $$a0.918$$b2020 000152993 593__ $$aTransplantation$$c2020$$dQ2 000152993 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000152993 700__ $$aRuiz, J.C. 000152993 700__ $$aFranco, A. 000152993 700__ $$aDiekmann, F. 000152993 700__ $$aRedondo, D. 000152993 700__ $$aCalviño, J. 000152993 700__ $$aSerra, N. 000152993 700__ $$0(orcid)0000-0002-1043-9979$$aAladrén, M.J.$$uUniversidad de Zaragoza 000152993 700__ $$aCigarrán, S. 000152993 700__ $$aManonelles, A. 000152993 700__ $$aRamos, A. 000152993 700__ $$aGómez, G. 000152993 700__ $$aGonzález Posada, J.M. 000152993 700__ $$aAndrés, A. 000152993 700__ $$aBeneyto, I. 000152993 700__ $$aMuñiz, A. L. 000152993 700__ $$aPerelló, M. 000152993 700__ $$aLauzurica, R. 000152993 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000152993 773__ $$g34, 1 (2020), e13767 [9 pp.]$$pClin. transplant.$$tClinical transplantation$$x0902-0063 000152993 85641 $$uhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85077894389&doi=10.1111%2fctr.13767&partnerID=40&md5=26fa9d88eb84967bd0974686c3a51ba4$$zTexto completo de la revista 000152993 8564_ $$s931680$$uhttps://zaguan.unizar.es/record/152993/files/texto_completo.pdf$$yVersión publicada 000152993 8564_ $$s1839932$$uhttps://zaguan.unizar.es/record/152993/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000152993 909CO $$ooai:zaguan.unizar.es:152993$$particulos$$pdriver 000152993 951__ $$a2025-10-17-14:12:58 000152993 980__ $$aARTICLE